Fast Track Program Reviews

FDA plans ultra-fast review of three psychedelic drugs

FDA moves to fast-track review of three psychedelic drug studies

The Food and Drug Administration (FDA) on Friday granted fast-track review to three companies studying psychedelic therapies to treat depression and post-traumatic stress disorder (PTSD), the latest step by the Trump administration toward possible approval.

· 3h

Trump Order Spurs FDA to Speed Reviews of Psychedelic Therapies

· 4h

FDA plans ultra-fast review of three psychedelic drugs following Trump directive

· 1d

Why Texas could uniquely benefit from Trump's order fast-tracking psychedelics

Texas' effort to launch clinical trials for ibogaine, an experimental treatment for PTSD and other mental health conditions, is getting a boost after President Donald Trump's new executive order to fa...

· 1d

FDA commissioner says decision on psychedelic treatments will be out 'quickly'

· 7h

Trump psychedelics order largely symbolic, analysts say

Hosted on MSN

FDA fast-tracks psychedelic drug reviews after Trump order

The FDA has launched a fast-track program for psychedelic therapies following President Trump’s executive order to accelerate treatments for serious mental illnesses. The initiative offers priority review vouchers to three companies developing psilocybin ...

Yahoo

US FDA approves first drug under new fast-track review program

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly//File Photo Dec 9 (Reuters ...